OTCMKTS:ADDXF Addex Therapeutics (ADDXF) Stock Price, News & Analysis $0.99 0.00 (0.00%) (As of 02/3/2023) Add Compare Share Share Today's Range$0.99▼$0.9950-Day Range$0.99▼$0.9952-Week Range$0.99▼$0.99VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Addex Therapeutics alerts: Email Address Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About Addex Therapeutics Stock (OTCMKTS:ADDXF)Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Read More ADDXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADDXF Stock News HeadlinesJuly 22, 2024 | markets.businessinsider.comAddex's Partner J&J Innovative Medicine Discontinues ADX71149 Development In EpilepsyJuly 22, 2024 | markets.businessinsider.comAddex’s Partner Discontinues ADX71149 development in EpilepsySeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 19, 2024 | msn.comJ&J ends work on Addex epilepsy drug candidate ADX71149: reportMay 5, 2024 | markets.businessinsider.comHere's what Wall Street expects from Addex Therapeutics's earningsMarch 24, 2024 | markets.businessinsider.comAddex Therapeutics earnings: here's what to expectMarch 22, 2024 | investing.comAddex Therapeutics Ltd (ADXN)January 25, 2024 | morningstar.comADRs Close Higher; Addex Therapeutics Climbs 21%September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.November 28, 2023 | markets.businessinsider.comAddex Therapeutics is about to announce its earnings — here's what to expectOctober 6, 2023 | benzinga.comAddex Announces Plan to Implement ADS Ratio ChangeSeptember 20, 2023 | markets.businessinsider.comAddex mGlu2 NAM Cognition Program Receives €4 Million GrantSeptember 4, 2023 | tmcnet.comAddex's Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in BrainJuly 24, 2023 | benzinga.comAddex mGlu2PAM Demonstrates Potential in Substance Use DisorderMay 12, 2023 | benzinga.comAddex Therapeutics Q1 EPS $(0.04) Up From $(0.97) YoY, Sales $542.43K Up From $264.20K YoYMay 10, 2023 | benzinga.comAddex Announces ADX71149 Phase 2 Epilepsy Clinical Study's Independent Interim Review Committee Recommends Continuing StudyApril 5, 2023 | finanznachrichten.deAddex Therapeutics: Addex Completes $5.0 Million Equity FinancingApril 5, 2023 | benzinga.comAddex Completes $5.0 Million Equity FinancingSee More Headlines Receive ADDXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ADDXF CUSIPN/A CIKN/A Webwww.addextherapeutics.com Phone41 22 884 1555FaxN/AEmployees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.25 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Timothy Mark Dyer (Age 54)Co-Founder, CEO & Director Dr. Roger G. Mills M.D. (Age 65)Chief Medical Officer & Director Mr. Lénaic Teyssédou (Age 36)Head of Fin. Dr. Jean-Philippe Rocher Ph.D. (Age 63)Head of Discovery - Chemistry Dr. Robert Lutjens (Age 54)Head of Discovery - Biology Dr. Mikhail Kalinichev Ph.D. (Age 54)Head of Translational Science Dr. Werner Henrichi Ph.D. (Age 79)Consultant More ExecutivesKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAeolus PharmaceuticalsOTCMKTS:AOLSAesther Healthcare AcquisitionNASDAQ:AEHAWAffymaxOTCMKTS:AFFYView All Competitors ADDXF Stock Analysis - Frequently Asked Questions How have ADDXF shares performed this year? Addex Therapeutics' stock was trading at $0.99 at the beginning of the year. Since then, ADDXF stock has increased by 0.0% and is now trading at $0.99. View the best growth stocks for 2024 here. How do I buy shares of Addex Therapeutics? Shares of ADDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ADDXF) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.